CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced that Andrew Hirsch, BIND’s president and chief executive officer, will present at the 8th Annual Biotech ShowcaseTM 2016 in San Francisco on Monday, January 11, 2016 at 4:00 p.m. PT.
